Showing results (71-80 of 128) with videos related to

Sort By:
Pageof 13
JTO Clinical and Research Reports|June 6, 2022
Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion-Positive NSCLCAlexander Drilon, Chao-Hua Chiu, Yun Fan, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 30, 2023
Lung Cancer Screening in Asia: An Expert Consensus ReportDavid Chi-Leung Lam, Chong-Kin Liam, Sita Andarini, et al.
The Lancet Regional Health. Western Pacific|January 6, 2025
Consensus on the lung cancer management after third-generation EGFR-TKI resistanceQing Zhou, Hongyun Zhao, Shun Lu, et al.
European Journal of Cancer (Oxford, England : 1990)|July 10, 2022
Nazartinib for treatment-naive EGFR-mutant non-small cell lung cancer: Results of a phase 2, single-arm, open-label studyDaniel S W Tan, Sang-We Kim, Santiago Ponce Aix, et al.
Nature Communications|March 27, 2023
Single cell analysis in head and neck cancer reveals potential immune evasion mechanisms during early metastasisHong Sheng Quah, Elaine Yiqun Cao, Lisda Suteja, et al.
The Lancet. Oncology|March 15, 2016
Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trialDong-Wan Kim, Ranee Mehra, Daniel S W Tan, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 17, 2019
Asian Thoracic Oncology Research Group Expert Consensus Statement on Optimal Management of Stage III NSCLCWan Ling Tan, Kevin L M Chua, Chia-Chi Lin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 5, 2021
Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non-Small Cell Lung Cancers on the LIBRETTO-001 TrialVivek Subbiah, Justin F Gainor, Geoffrey R Oxnard, et al.
Cell Reports. Medicine|November 18, 2020
Human Tumor-Infiltrating MAIT Cells Display Hallmarks of Bacterial Antigen Recognition in Colorectal CancerShamin Li, Yannick Simoni, Etienne Becht, et al.
Nature Cancer|May 13, 2026
Nivolumab plus chemoradiotherapy followed by nivolumab with or without ipilimumab for untreated locally advanced stage III NSCLC: a randomized phase 3 trialSolange Peters, Daniel S W Tan, David E Gerber, et al.
Pageof 13